Enveric Biosciences, Inc.
ENVB
$5.90
$0.081.38%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 17.41% | -10.37% | |||
| Depreciation & Amortization | 1.00% | -50.62% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -25.61% | 15.15% | |||
| Operating Income | 25.61% | -15.15% | |||
| Income Before Tax | 25.62% | -15.30% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 25.62% | -15.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 25.62% | -15.30% | |||
| EBIT | 25.61% | -15.15% | |||
| EBITDA | 26.04% | -17.69% | |||
| EPS Basic | 7.15% | 20.15% | |||
| Normalized Basic EPS | 48.64% | 20.15% | |||
| EPS Diluted | 7.15% | 20.15% | |||
| Normalized Diluted EPS | 48.64% | 20.15% | |||
| Average Basic Shares Outstanding | 44.80% | 44.39% | |||
| Average Diluted Shares Outstanding | 44.80% | 44.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||